Derivative exercise or conversion — not an open-market buy.
Loading…
Traded May 15, 2026 · Filed May 18, 2026
Moderna's President sold $2.58M of Moderna shares. It was planned long ago, so it says very little.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell
open market sale
Code S — open-market or private sale
~$2,581,462
Shares × reported transaction price
14 days after results of May 1, 2026, 77 days before results of Jul 31, 2026
Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results
Closed at $49.04 on May 15, 2026, 119% above its 52-week low and 15% below its high, little changed over the previous 30 trading days
52-week range $22.36 (Nov 20, 2025) to $57.80 (Mar 4, 2026), 75% of the way up, from 251 adjusted closes. 30 trading days earlier: $49.20 on Apr 2, 2026. Describes the past only, not a forecast
Footnote references a pre-arranged trading plan (Rule 10b5-1)
Only flagged when a footnote says so; never inferred
A securities lawsuit naming the company as a defendant was filed on Aug 9, 2024 in the U.S. District Court, D. Massachusetts. A filing is an allegation, not a finding.
Wentz v. Moderna, Inc., docket 1:24-cv-12058, via CourtListener (court records). Nature of suit 850, company named as first defendant
| After | Stock | S&P 500 | Difference |
|---|---|---|---|
| 7 days | +2.9% | +2.3% | +0.6% |
| 30 days | +39.9% | +1.8% | +38.1% |
| 90 days | +41.0% | +5.3% | +35.7% |
Past results only. Not a forecast.
Derivative exercise or conversion — not an open-market buy.
Derivative exercise or conversion — not an open-market buy.
Officer sold ~$2.74M of Moderna
Scheduled in advance
